نتایج جستجو برای: chronic myeloid leukemia

تعداد نتایج: 744967  

Journal: :acta medica iranica 0
ali esfahani hematology and oncology research center, tabriz university of medical sciences, tabriz, iran. zohreh ghoreishi department of nutrition and biochemistry, school of health sciences, tehran university of medical sciences, tehran, iran. alireza nikanfar hematology and oncology research center, tabriz university of medical sciences, tabriz, iran. zohreh sanaat hematology and oncology research center, tabriz university of medical sciences, tabriz, iran. amir ghorbanihaghjo drug applied research center, tabriz university of medical sciences, tabriz, iran.

chemotherapeutic agents used in patients with cancer cause to generate the enormous amounts of free radicals associated with cell injury. in this study we assess the effects of chemotherapy regimen on oxidant/antioxidant status in patients with acute myeloid leukemia (aml). 38 newly diagnosed patients with acute myeloid leukemia were recruited in this study. all patients received cytarabine and...

Journal: :Neurologia 2017
F Pérez-Bartolomé C Sanz-Pozo S Darío Rosati E Santos-Bueso J Porta-Etessam

8. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251—9. 9. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, o...

Journal: :Blood 2010
Juraj Bies Marek Sramko Joanna Fares Michael Rosu-Myles Steven Zhang Richard Koller Linda Wolff

Inactivation of p15INK4b, an inhibitor of cyclin-dependent kinases, through DNA methylation is one of the most common epigenetic abnormalities in myeloid leukemia. Although this suggests a key role for this protein in myeloid disease suppression, experimental evidence to support this has not been reported. To address whether this event is critical for premalignant myeloid disorders and leukemia...

Journal: :Haematologica 2013
Sarah Abu Kar Anna Jankowska Hideki Makishima Valeria Visconte Andres Jerez Yuka Sugimoto Hideki Muramatsu Fabiola Traina Manuel Afable Kathryn Guinta Ramon V Tiu Bartlomiej Przychodzen Hirotoshi Sakaguchi Seiji Kojima Mikkael A Sekeres Alan F List Michael A McDevitt Jaroslaw P Maciejewski

Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia. Recently, recurrent mutations in spliceosomal genes have been discovered. We investigated the contribution of U2AF1, SRSF2 and SF3B1 mutations in the pathogenesis of chronic myelo...

Journal: :international journal of hematology-oncology and stem cell research 0
mahdi zahed panah department of medical laboratory sciences, faculty of allied medicine, qazvin university of medical sciences, qazvin, iran mohsen nikbakht hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran seyed mehdi sajjadi cellular and molecular research center, birjand university of medical sciences, birjand, iran shahrbano rostami hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran amir hossein norooznezhad medical biology research center, kermanshah university of medical sciences, kermanshah, iran hosein kamranzadeh fumani hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran

background: the conventional chemotherapeutic regimens which applied for treatment of acute myeloid leukemia (aml) mostly target tumor bulk but not leukemic stem cells (lscs). aberrant expression or activation of mediators such as osteopontin (opn) or pi3k/pten/akt/mtor pathway plays a key role in making prone to develop leukemia. preventing or treating cancer by curcumin (cur) has been suggest...

Journal: :nephro-urology monthly 0
athanasios dellis department of urology, naval and veterans hospital, athens, greece dimitrios boutsis department of haematology, naval and veterans hospital, athens, greece evangelos spyropoulos department of urology, naval and veterans hospital, athens, greece ioannis galanakis department of urology, naval and veterans hospital, athens, greece angelos panagopoulos department of urology, naval and veterans hospital, athens, greece athanasios papatsoris university department of urology, sismanoglio hospital, athens, greece; university department of urology, sismanoglio hospital, kanari 9, gr-10671, athens, greece. tel/fax +30-2108044703

testicular chloroma is an unusual form of extramedullary acute myeloid leukemia. we present a rare case that after chemotherapy relapsed with the appearance of metachronous testicular chloroma and we suggest prophylactic radiotherapy.

2013
Jason Gotlib Julia E. Maxson Tracy I. George Jeffrey W. Tyner

In clinical practice, neutrophilia most commonly relates to leukemoid reactions due to chronic infections, inflammatory diseases, or various types of malignancies. Cytokine-driven neutrophilia accompanying plasma cell neoplasms is a well-described association. Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm, with only ;200 patients reported to date, mostly culled from ...

2017
Jorge Cortes Moshe Talpaz Hedy P. Smith David S. Snyder Jean Khoury Kapil N. Bhalla Javier Pinilla-Ibarz Richard Larson David Mitchell Scott C. Wise Thomas J. Rutkoski Bryan D. Smith Daniel L. Flynn Hagop M. Kantarjian Oliver Rosen Richard A. Van Etten

A vailable tyrosine kinase inhibitors for chronic myeloid leukemia bind in an adenosine 5'-triphosphate-binding pocket and are affected by evolving mutations that confer resistance. Rebastinib was identified as a switch control inhibitor of BCR-ABL1 and FLT3 and may be active against resistant mutations. A Phase 1, first-in-human, single-agent study investigated rebastinib in relapsed or refrac...

2006
Claude Stoll Francis Oberling Marie-Paule Roth

The frequency of sister chromatid exchange (SCE) was analyzed in bone marrow cells of 16 patients with chronic myeloid leukemia. We have compared the SCE frequency in these patients, in both chronic and blastic phases of the dis ease, to that of normal individuals. The frequency of SCE in blastic-phase chronic myeloid leukemia patients (mean, 1.86/ cell) was significantly lower than that in chr...

Journal: :Haematologica 2013
Dan P Zandberg Ting-Ying Huang Xuehua Ke Maria R Baer Steven D Gore Sheila Weiss Smith Amy J Davidoff

Prior studies have investigated patients' characteristics, treatments, and outcomes for older adults with myelodysplastic syndromes, but most failed to distinguish chronic myelomonocytic leukemia. Recognizing potentially important differences between the diseases, we undertook a population-based comparison of baseline characteristics, treatments, and outcomes between older adults with chronic m...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید